Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VK 2019

Next Previous
Drug Profile

VK 2019

Alternative Names: VK-2019

Latest Information Update: 29 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fox Chase Chemical Diversity Center; Wistar Institute
  • Developer Cullinan Apollo
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epstein-Barr virus nuclear antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nasopharyngeal cancer

Most Recent Events

  • 23 Jan 2025 Thomas Jefferson University plans a phase Ib trial for Diffuse large B-cell lymphoma (Second-line therapy or greater) in USA (NCT06789159)
  • 02 Jun 2023 Efficacy, adverse events and pharmacokinetic data from a phase II trial in Nasopharyngeal cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 19 Oct 2020 Cullinan Oncology terminates phase I/II clinical trials in Nasopharyngeal cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in France, Hong Kong, China, USA due to lack of efficacy (NCT03682055)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top